Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
OnKure Therapeutics (OKUR)
NASDAQ:OKUR
Holding OKUR?
Track your performance easily
OKUR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.80 - $81.50
Previous Close$17.5
Volume110.85K
Average Volume (3M)35.92K
Market Cap
$221.42M
Enterprise Value$145.57M
Total Cash (Recent Filing)$76.67M
Total Debt (Recent Filing)$823.00K
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Nov 06, 2024EPS Estimate
-$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.85
Shares Outstanding3,342,881
10 Day Avg. Volume65,384
30 Day Avg. Volume35,923
Standard Deviation0.29
R-Squared0.00129
Alpha-0.00763
Financial Highlights & Ratios
Price to Book (P/B)0.76
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.63
Forecast
1Y Price Target
$35.33Price Target Upside101.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Ownership Overview
8.71% Insiders
7.46% Mutual Funds
― Other Institutional Investors
76.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OKUR FAQ
What was OnKure Therapeutics’s price range in the past 12 months?
OnKure Therapeutics lowest stock price was $9.80 and its highest was $81.50 in the past 12 months.
What is OnKure Therapeutics’s market cap?
Currently, no data Available
When is OnKure Therapeutics’s upcoming earnings report date?
OnKure Therapeutics’s upcoming earnings report date is Nov 06, 2024 which is in 2 days.
How were OnKure Therapeutics’s earnings last quarter?
OnKure Therapeutics released its earnings results on Aug 13, 2024. The company reported -$1.6 earnings per share for the quarter, missing the consensus estimate of -$1 by -$0.6.
Is OnKure Therapeutics overvalued?
According to Wall Street analysts OnKure Therapeutics’s price is currently Undervalued.
Does OnKure Therapeutics pay dividends?
OnKure Therapeutics does not currently pay dividends.
What is OnKure Therapeutics’s EPS estimate?
OnKure Therapeutics’s EPS estimate is -$0.7.
How many shares outstanding does OnKure Therapeutics have?
OnKure Therapeutics has 12,652,811 shares outstanding.
What happened to OnKure Therapeutics’s price movement after its last earnings report?
OnKure Therapeutics reported an EPS of -$1.6 in its last earnings report, missing expectations of -$1. Following the earnings report the stock price went up 2.985%.
Which hedge fund is a major shareholder of OnKure Therapeutics?
Among the largest hedge funds holding OnKure Therapeutics’s share is Highbridge Capital Management LLC. It holds OnKure Therapeutics’s shares valued at 4M.
---
OnKure Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.33 (101.89% Upside)
$35.33 (101.89% Upside)
Hedge Fund Trend
Increased
By 17.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 9.2%
Last 30 Days ▼ 9.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-78.36%
12-Months-Change
Fundamentals
Return on Equity
-54.00%
Trailing 12-Months
Asset Growth
-46.83%
Trailing 12-Months
Company Description
OnKure Therapeutics
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
---
OKUR Stock 12 Month Forecast
Average Price Target
$35.33
▲(101.89% Upside)
Technical Analysis
Foghorn Therapeutics
―
Heron Therapeutics
―
Seres Therapeutics
―
Praxis Precision Medicines
―
Best Analysts Covering OKUR
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-49.60%
reiterated a sell rating 7 months ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -49.60% per trade.
---